URB754
Supposed MAGL inhibitor: the activity came from a mercury impurity in the commercial batch; reported in 2013 in illegal products in Japan.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₁₆H₁₄N₂O₂
CAS 86672-58-4
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 266.29 g/mol
Updated on
In plain terms
URB754 was presented in 2005 as a blocker of an enzyme of the cannabinoid system, and the effect then turned out to come from a mercury impurity in the commercial sample: the molecule itself does not block this enzyme. It has also been found in Japan in illegal products sold as designer drugs. It is a textbook case of reagent error.
Receptors and activity
Target network
- Binds or modulates
The lower the cited value, the closer the target sits to URB754: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of URB754.
MAGLMAGL found in 5 regions of the body
Map sources
- Takahata K et al. First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with (18)F-T-401. Eur J Nucl Med Mol Imaging, 2022 (new tab)
- Ludányi A et al. Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience, 2011 (new tab)
- Spoto B et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie, 2006 (new tab)
- Human Protein Atlas. MGLL expression summary (new tab)
Cited values
- MAGLModulatorno measured value cited
no inhibition found (rat brain, Saario et al. 2006; recombinant human MAGL, Vandevoorde et al. 2007); the activity reported in 2005 (IC50 200 nM) comes from an impurity (Tarzia et al. 2007)
Pharmacology
URB754 is interesting for what it is not. Arising from the screening of a commercial chemical library, it was reported in 2005 in Nature Neuroscience as a potent inhibitor of monoacylglycerol lipase (MAGL) (Makara et al. 2005). The correction came in two stages. In 2006, Saario et al., at the University of Kuopio, found no inhibition of 2-AG hydrolysis or of FAAH in rat brain, and concluded that the compound could not serve as a starting point for developing MAGL inhibitors (Saario et al. 2006). In 2007, analysis of the commercial sample by HPLC/MS, NMR and EI/MS showed that the activity attributed to URB754 was due to an impurity, bis(methylthio)mercurane, with an IC50 of 11.9 nM on MAGL (Tarzia et al. 2007). An erratum was published for the 2005 article in January 2007 (Nat Neurosci 10:134). The same year, Vandevoorde et al. observed no effect on recombinant human MAGL (Vandevoorde et al. 2007). The compound was also reported in 2013 in illegal products in Japan, together with 4-methylbuphedrone (Uchiyama et al. 2013). No pharmacokinetic, metabolic or human data were found in the sources consulted.
Key sources.
- Saario et al., Chem Biol 2006: URB754 has no effect on the hydrolysis or the signalling capacity of 2-AG in the rat brain (new tab)PMID 16931330
- Tarzia et al., Ann Chim 2007: identification of a bioactive impurity in a commercial sample of URB754 (new tab)PMID 17970304
- Makara et al., Nat Neurosci 2005: initial attribution of the activity (erratum published in 2007) (new tab)PMID 16116451
- Vandevoorde et al., Br J Pharmacol 2007: URB602 and URB754 do not behave as selective or potent MAGL inhibitors (new tab)PMID 17143303
- Uchiyama et al., Forensic Sci Int 2013: URB-754, a new type of designer drug, and 12 synthetic cannabinoids detected in illegal products (new tab)PMID 23063179
- PubChem, URB754, CID 848487 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
History
- Source
- Entirely synthetic compound with no known natural occurrence. It served as a laboratory reagent, but it was also reported in 2013 as a « new type of designer drug » in illegal products detected in Japan, together with 4-methylbuphedrone (Uchiyama et al. 2013). The activity that had given it its pharmacological interest was not its own.
Origin
Research tool
No known biosynthetic pathway: a synthetic molecule. It is a benzoxazinone, 6-methyl-2-(4-methylanilino)-3,1-benzoxazin-4-one.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. No marketing authorisation was found.
- France
Not classified: URB754 does not appear in the ANSM consolidated list of narcotics (updated 16/02/2026); on a literal reading, its structure (a benzoxazinone) falls within none of the generic families of Annex IV (indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, indole or indazole carboxylates and carboxamides, cyclohexylphenols, benzo[c]chromene nucleus). No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Saario et al., Chem Biol 2006: URB754 has no effect on the hydrolysis or the signalling capacity of 2-AG in the rat brain (new tab)PMID 16931330
- Tarzia et al., Ann Chim 2007: identification of a bioactive impurity in a commercial sample of URB754 (new tab)PMID 17970304
- Makara et al., Nat Neurosci 2005: initial attribution of the activity (erratum published in 2007) (new tab)PMID 16116451
- Vandevoorde et al., Br J Pharmacol 2007: URB602 and URB754 do not behave as selective or potent MAGL inhibitors (new tab)PMID 17143303
- Uchiyama et al., Forensic Sci Int 2013: URB-754, a new type of designer drug, and 12 synthetic cannabinoids detected in illegal products (new tab)PMID 23063179
- PubChem, URB754, CID 848487 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
Identifiers
Names
- IUPAC name
- 6-methyl-2-(4-methylanilino)-3,1-benzoxazin-4-one
- Other names
- URB 754 · URB-754
Identifiers
- Formula
- C₁₆H₁₄N₂O₂
- CAS
- 86672-58-4
- PubChem CID
- 848487(new tab)
- InChIKey
- GFWNGVKCDGYFKG-UHFFFAOYSA-N
- SMILES
- CC1=
CC= C(C= C1) NC2= NC3= C(C= C(C= C3) C) C(= O) O2
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.